HDF Transformative Research Award supports collaborative teams testing novel disease mechanisms, tools, and therapeutic approaches to advance Huntington's disease research and treatment.
Funder: Huntington's Disease Foundation
Due Dates: January 15, 2027 (LOIs open) | February 19, 2027 (LOIs due) | April 1, 2027 (Full proposal invitations) | May 14, 2027 (Invited full proposals due)
Funding Amounts: $300,000–$500,000 per award annually for up to two years; indirect costs capped at 15% of direct costs
Summary: Supports collaborative teams testing exceptionally novel disease mechanisms, tools, and therapeutic approaches to advance Huntington’s disease treatments.
Key Information: The contact PI must have an academic appointment and institutional commitment; full proposals are invitation-only.
The Huntington’s Disease Foundation (HDF) Transformative Research Award supports collaborative teams developing and testing new ideas that could transform Huntington’s disease (HD) research or treatment. It funds fundamental disease mechanisms, conceptually novel therapeutic approaches, and tools or technologies not previously applied to HD research. Incremental advances on published work are excluded.
Areas of interest include whether modulating somatic repeat instability can modify disease, whether cellular, biochemical, or molecular insights predict disease, and how unexplored therapeutics or biomarkers could reach clinical application. Projects identifying disease-modifying targets are encouraged. HDF prioritizes exceptional novelty paired with a credible research path and a clear connection to potential therapies. Partnerships across disciplines, academia and industry, and expertise from outside the HD field are strongly encouraged.